Literature DB >> 25989850

Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap.

Sandip Basu1, Mitali Dandekar, Amit Joshi, Anil D'Cruz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25989850     DOI： 10.1007/s00259-015-3058-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  29 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

2.  Resveratrol, thyroid cancer, and iodide: drink up?

Authors:  John C Morris
Journal:  Thyroid       Date:  2010-02       Impact factor: 6.568

3.  Resveratrol increases iodide trapping in the rat thyroid cell line FRTL-5.

Authors:  Hichem Sebai; Sonia Hovsépian; Elodie Ristorcelli; Ezzedine Aouani; Dominique Lombardo; Guy Fayet
Journal:  Thyroid       Date:  2010-02       Impact factor: 6.568

4.  Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.

Authors:  Quang T Luong; James O'Kelly; Glenn D Braunstein; Jerome M Hershman; H Phillip Koeffler
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

5.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

6.  Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.

Authors:  F Grünwald; C Menzel; H Bender; H Palmedo; R Otte; R Fimmers; J Risse; H J Biersack
Journal:  J Nucl Med       Date:  1998-11       Impact factor: 10.057

7.  Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.

Authors:  Fumihiko Furuya; Hiroki Shimura; Hideyo Suzuki; Katsumi Taki; Kazuyasu Ohta; Kazutaka Haraguchi; Toshimasa Onaya; Toyoshi Endo; Tetsuro Kobayashi
Journal:  Endocrinology       Date:  2004-02-19       Impact factor: 4.736

8.  [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.

Authors:  Fabienne Iten; Beat Muller; Christian Schindler; Helmut Rasch; Christoph Rochlitz; Daniel Oertli; Helmut R Maecke; Jan Muller-Brand; Martin A Walter
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

9.  Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas.

Authors:  Kenneth B Ain; Charles Lee; Kevin D Williams
Journal:  Thyroid       Date:  2007-07       Impact factor: 6.568

10.  Phase II trial of sorafenib in metastatic thyroid cancer.

Authors:  Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  4 in total

1.  Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?

Authors:  Sandip Basu; Ashwini Kalshetty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-24       Impact factor: 9.236

Review 2.  Changing Paradigm in Treatment of Differentiated Thyroid Cancer.

Authors:  Krishna B A; Mohammed Saleel K
Journal:  Indian J Surg Oncol       Date:  2022-03-22

3.  Hyperplastic thymus with increased angiogenesis is correlated with elevated serum thyroglobulin level in differentiated thyroid cancer patients with TENIS syndrome.

Authors:  Guangjian Zhang; Rui Gao; Yuanbo Wang; Yan Liu; Juan Li; Xi Jia; Yiqian Liang; Aimin Yang
Journal:  Oncotarget       Date:  2017-12-15

4.  Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]iodine scintigraphy in recurrent differentiated thyroid cancer.

Authors:  Matthias Dittmann; José Manuel Gonzalez Carvalho; Kambiz Rahbar; Michael Schäfers; Michael Claesener; Burkhard Riemann; Robert Seifert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-04       Impact factor: 9.236
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.